GBGernot Beutel

Gernot Beutel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gernot Beutel has a total of 312 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors associated with persistent post-COVID-19 condition and functional limitation four years after SARS-CoV-2 infection

    by M. Faraj, A. Grosshennig, N. Goedecke, M. Dirks, A. K. Hennemann, S. Greten, H. Ehrenreich, R. Blasczyk, K. Weissenborn, G. Beutel

    Post-COVID-19 condition (PCC) can persist for years after acute SARS-CoV-2 infection, but factors associated with long-term persistence and functional outcomes remain incompletely understood. In this longitudinal cohort study, adults with confirmed SARS-CoV-2 infection who had volunteered for plasma donation completed surveys approximately 16 and 48 months after infection. Acute-phase demographic characteristics and symptoms were examined for associations with PCC and persistent PCC using multivariable logistic regression analyses. Persistent symptoms at follow-up and their associations with functional limitation, assessed with the Post-COVID Functional Status (PCFS) scale, were examined separately. Among 992 participants in 2021, 609 (61.4%) met criteria for PCC, while 333 of 568 participants (58.6%) fulfilled PCC criteria in 2024. Older age, fatigue, palpitations, depressive symptoms, and concentration and memory difficulties during acute infection were associated with PCC at both follow-up assessments, whereas female sex was associated with PCC only at the 4-year follow-up. Among participants with PCC in 2021, 77.4% continued to meet PCC criteria in 2024; concentration difficulties, depressive symptoms, and older age were associated with persistent PCC. Functional limitation was associated with persistent fatigue, concentration difficulties, dyspnea at rest, and depressive symptoms. These findings demonstrate the persistent nature of PCC and highlight the need for further research into the mechanisms behind PCC and the development of therapeutic strategies.

  • Open Access

    Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy

    by Katja Krüger, Razif Gabdoulline, Martin Wichmann, Bernhard M. W. Schmidt, Katharina Götze, Krischan Braitsch, Laura Schmalbrock, Lars Bullinger, Franziska Westendorf, Walter Fiedler, et al.

    Chronic kidney disease (CKD) before treatment and renal function decline during treatment are common in elderly patients receiving hypomethylating agents (HMAs) and venetoclax (VEN). This retrospective multicenter study of 130 newly diagnosed older acute myeloid leukemia (AML) patients evaluated the prognostic impact of renal function before and during the first treatment cycle. A total of 56 patients (43%) had CKD, and 49 (38%) developed acute kidney injury (AKI) during treatment. AKI occurrence was associated with laboratory tumor lysis syndrome (LTLS). CKD before treatment showed a trend towards a lower overall response rate (ORR, OR 0.5, p = 0.07) in multivariable analysis (MVA) and inferior relapse-free survival (RFS, HR 2.16, p = 0.06) in univariate analysis (UVA), but not MVA (RFS, HR 1.93, p = 0.15). CKD did not affect overall survival (OS) or event-free survival (EFS). AKI during HMA/VEN therapy was associated with significantly higher 30-day and 60-day mortality rates and emerged as an independent prognostic factor for inferior OS (HR 1.86, p = 0.01) and EFS (HR 1.81, p = 0.007). RFS did not differ significantly by AKI status. Sepsis was a more frequent cause of death in patients with vs. without AKI (33% vs. 5%). In conclusion, kidney function is a key prognostic factor in HMA/VEN-treated patients, warranting further study on treatment adjustments and supportive care.


  • Author’s Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al.

    by Simone Cesaro, Per Ljungman, Malgorzata Mikulska, Hans H. Hirsch, David Navarro, Catherine Cordonnier, Varun Mehra, Jan Styczynski, Francesco Marchesi, Jose Luis Pinana, et al.


  • Open Access

    Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)

    by Simone Cesaro, Per Ljungman, Malgorzata Mikulska, Hans H. Hirsch, David Navarro, Catherine Cordonnier, Varun Mehra, Jan Styczynski, Francesco Marchesi, Jose Luis Pinana, et al.

    In the post-pandemic years, SARS-CoV-2 morbidity and mortality declined due to less pathogenic variants, active and passive immunization, and antiviral therapies. However, patients with hematological malignancies and/or undergoing hematopoietic cell transplantation (HCT) remain at increased risk for poor outcomes. Therefore, adherence to contact and droplet precautions is essential to avoid transmission, especially during epidemic waves. Detection of viral RNA by nucleic acid testing of naso-oro-pharyngeal samples is the gold standard for diagnosis due to its high sensitivity and specificity. Direct antigen testing allows for rapid management decisions if positive, but has a low sensitivity, especially in asymptomatic patients. Active immunisation is the key to prevention and may require annual matching to circulating variants. Passive immunization with SARS-CoV-2 neutralizing anti-antibodies lost its indication due to the emergence of immune escape variants. Convalescent plasma has been proposed for passive immunization but is not readily available in most centres. For symptomatic patients, early antiviral treatment with nirmatrelvir/ritonavir or remdesivir may reduce the risk of progression to severe-critical COVID-19. Prolonged administration, repeated courses, and a combination of antivirals are considered for patients with clinical or virological failure to antiviral monotherapy. In severe-critical COVID-19, dexamethasone or drugs downregulating the inflammatory cytokine responses (anti-Il-6/anti-IL-2 agents, Janus kinase inhibitor) are recommended, together with the best supportive and intensive care, but care should be exercised in immunosuppressed patients. Deferral of intensive chemotherapy, HCT conditioning, T-cell-based immunotherapy, or T-cell engaging antibodies are considered for patients with COVID-19, whereas deferral decisions are taken on a case-by-case basis for asymptomatic patients with confirmed SARS-CoV-2 infection.


  • Top Cited Papers
    Open Access

    Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)

    by Kirsi Manz, Florian H. Heidel, Steffen Koschmieder, Rudolf Schlag, Jörg Lipke, Frank Stegelmann, Martin Griesshammer, Martine Klausmann, Carl Crodel, Andreas Hochhaus, et al.

    Myeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients’ quality of life and ability to perform daily activities. Recent studies showed differences in the perception of physician- versus patient-reported symptom burden. However, studies directly comparing patient- and physician-reported ratings are lacking. Here, a retrospective analysis on symptom burden of 3979 MPN patients of the Bioregistry of the German Study Group for MPN was conducted to intra-individually compare physician and patient reports collected at the same time. Cohen’s kappa was calculated to assess the degree of agreement between patient and physician reports. Factors influencing baseline symptom severity were identified using linear regression and adjusted Cox models were calculated to investigate the effect of symptom burden on survival. MPN patients had a high symptom burden, which neither decreased over time nor upon cytoreductive therapy. All symptoms were more frequently reported by patients compared to physicians. Agreement remained low and only slightly improved when considering a higher threshold for patient symptom severity. Patients with severe symptom burden had inferior survival compared to patients with less severe symptoms. Assessment of symptom burden in MPN is therefore insufficient and patient-reported outcome tools need to be implemented into clinical routine.


  • Top Cited Papers
    Open Access

    A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

    by Rabia Shahswar, Razif Gabdoulline, Katja Krueger, Martin Wichmann, Katharina S. Götze, Krischan Braitsch, Manja Meggendorfer, Laura Schmalbrock, Lars Bullinger, Franziska Modemann, et al.

    Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.6 years) with R/R AML was to establish a prognostic risk score. Overall response was documented in 106 (44%) patients. With a median follow-up of 31.5 months, 179 deaths were recorded. Median overall survival (mOS) was 7.9 months. In multivariate analysis of the subgroup with molecular information (n = 174), risk factors for inferior survival included the presence of extramedullary disease, HMA pretreatment and mutations in NF1, PTPN11, FLT3, and TP53, whereas mutated SF3B1 was identified as favorable risk factor. These risk factors were subsequently applied to construct an HR-weighted risk model that allocated patients to one of three risk groups with significantly different survival outcomes: favorable (n = 46; mOS 21.4 months), intermediate (n = 75; mOS 7.5 months), and adverse (n = 53; mOS 4.6 months; p < 0.001). The model was validated in 189 AML patients treated with HMA/VEN in first line. This clinical-molecular, 3-tiered venetoclax prognostic risk score (VEN-PRS) for HMA/VEN treatment outcomes in R/R AML patients will support the selection of appropriate treatment options in this high-risk population.


  • Top Cited Papers

    GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines

    by Dyke Ferber, Isabella C. Wiest, Georg Wölflein, Matthias P. Ebert, Gernot Beutel, Jan-Niklas Eckardt, Daniel Truhn, Christoph Springfeld, Dirk Jäger, Jakob Nikolas Kather


  • Open Access

    Data-driven grading of acute graft-versus-host disease

    by Evren Bayraktar, Theresa Graf, Francis A. Ayuk, Gernot Beutel, Olaf Penack, Thomas Luft, Nicole Brueder, Gastone Castellani, H. Christian Reinhardt, Nicolaus Kröger, et al.

    Despite advances in allogeneic hematopoietic cell transplantation, acute graft-versus-host disease (aGVHD) remains its leading complication, yet with heterogeneous outcomes. Here, we analyzed aGVHD phenotypes and clinical classifications in depth in large, multicenter cohorts involving 3019 patients and addressed prevailing gaps by developing data-driven models. We compared, tested and verified these along with all conventional classifications in independent cohorts and found that data-driven grading outperformed conventional grading in Akaike information criterion and concordance index metrics. Data-driven classifications refined aGVHD assessment with up to 12 severity grades, which were associated with distinct nonrelapse mortality (NRM) and confirmed the key role of intestinal aGVHD. We developed an online calculator for physicians to implement principal component-derived grading (PC1). These results provide substantial insight into the evaluation of aGVHD phenotypes and multiorgan involvement, which relegates the exclusive reporting of overall aGVHD severity grades in transplant registries and clinical trials. Data-driven aGVHD grading provides an expandable platform to refine classification and transplant risk assessment.


  • Mit einer Tumordiagnose auf der Intensivstation

    by Gernot Beutel, Tobias Liebregts, Boris Böll


  • Open Access

    MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

    by Katrin Teich, Michael Stadler, Razif Gabdoulline, Jyoti Kandarp, Clara Wienecke, Bennet Heida, Piroska Klement, Konstantin Büttner, Letizia Venturini, Martin Wichmann, et al.

    Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Predictors of response to DLIs are not well established. We evaluated measurable residual disease (MRD) before, 30 and 90 days after DLI treatment as biomarkers of response. MRD was assessed by next-generation sequencing in 76 DLI-treated acute myeloid leukemia patients. MRD status before DLI treatment was independently prognostic for event-free survival (EFS, p < 0.001) and overall survival (OS, p < 0.001). Within 90 days of DLI treatment, 73% of MRD+ patients converted to MRD− and 32% of patients without remission achieved remission. MRD status 90 days after DLI treatment was independently prognostic for the cumulative incidence of relapse (CIR, p = 0.011) and relapse-free survival (RFS, p = 0.001), but not for OS. To evaluate the role of DLI treatment in MRD− patients, 23 MRD− patients who received DLIs were compared with a control cohort of 68 MRD− patients not receiving DLIs. RFS (p = 0.23) and OS (p = 0.48) were similar between the two cohorts. In conclusion, MRD is prognostic before (EFS, OS) and after (CIR, RFS) DLI treatment and may help in the selection of patients who benefit most from DLIs.